- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04153162
Non-Invasive Radiation Ablation in Patients With Hypertrophic CardioMyopathy: NIRA-HOCM (NIRA-HOCM)
Non-Invasive Radiation Ablation for Septal Reduction in Patients With Hypertrophic Obstructive CardioMyopathy: First in Man Pilot Study
Hypertrophic cardiomyopathy (HCM) is a common disease of the heart which causes thickening of the heart muscle.
HCM primarily affects the muscle of the main pumping chamber of the heart (the left ventricle) and particularly the septum (this is the muscular wall which separates the right and left side of the heart). In a subgroup of patients, the thickened heart muscle at the septum prevents blood from leaving the heart during contraction (this is called obstruction). This form of the disease is called hypertrophic obstructive cardiomyopathy (HOCM).
HOCM is a common cause of shortness of breath, chest pain and dizzy spells. These symptoms are treated with tablets and if symptoms are uncontrolled, patients are often offered invasive treatment to get rid of some of the thick heart muscle and reduce obstruction. This is achieved either by:
- open heart surgery (myectomy) where a surgeon cuts out the thick muscle
- injection of alcohol to the thick heart muscle via a tube in the wrist or groin (alcohol septal ablation). The alcohol thins the heart muscle at the point of obstruction, mimicking the effects of myectomy.
Unfortunately, some patients are not suitable for both these procedures.
This study will test whether radiotherapy, usually used for the treatment of tumours, can be used to destroy the thick heart muscle at the point of obstruction safely and effectively. Study patients will be monitored following the procedure and the investigators plan to measure the levels of heart muscle thinning, reduction of obstruction and improvement in symptoms and importantly document any side effects.
Radiotherapy works by precisely targeting high energy X-rays (ionising radiation) at a specific area of the body with the aim of destroying abnormal tissue. CyberKnife is one of the latest radiotherapy delivery systems, which will deliver highly focussed and accurate radiotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Costas O'Mahony, FRCP, MD
- Email: constantinos.omahony@nhs.net
Study Locations
-
-
-
London, United Kingdom, EC1A 7BE
- Barts Heart Centre
-
Contact:
- Costas O'Mahony, FRCP, MD
- Email: constantinos.omahony@nhs.net
-
Sub-Investigator:
- Dan Jones, MRCP PhD
-
Sub-Investigator:
- Charles Knight, FRCP, MD
-
Principal Investigator:
- Costas O'Mahony, FRCP, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Limiting, drug refractory symptoms secondary to left ventricular outflow tract obstruction
- Previously failed invasive septal reduction therapy (ethanol septal ablation/surgical myectomy) or inability to perform invasive septal reduction due to increased risk/co-morbidities/anatomical considerations following specialist MDT review
- A device (permanent pacemaker or implantable cardioverter defibrillator) in situ.
- Ventricular septal thickness at site ablation ≥ 16mm.
- Patient able to tolerate lying flat for one hour
- High target-surrogacy of ICD/pacing lead for cardiac motion (from cardiac-gated MRI or cardiac-gated CT with the patient in pacing mode used for treatment)
- Successful completion of ICD lead tip tracking test ("patient dummy run") with the patient in pacing mode used for treatment
- Adult Patients aged 18 and over willing and able to give written informed consent
Exclusion Criteria:
- New York Heart Association I-II
- Canadian Cardiovascular Society class 1-2
- Follow-up impossible (e.g. no fixed abode)
- Weight of patient that exceeds the maximum limit of CMR table (170kg)
- Subjects of childbearing potential unless βHCG negative and on contraception
- Lack of cardiac device with anti-bradycardia pacing capabilities
- Previous chest radiotherapy
- Inability to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stereotactic body radiation therapy
In patients with HCM and refractory symptoms from LVOTO, stereotactic body radiation therapy will be delivered locally to relieve symptoms
|
Stereotactic body radiation therapy delivered to reduce LVOTO in patients with HCM
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demonstrate acute (≤ 90 days) safety of non-invasive SBRT.
Time Frame: 90 days
|
The primary safety endpoint is defined as serious adverse events (SAEs) that are possibly/probably/definitely related to study treatment, based on previously published data for expected invasive alcohol septal-ablation procedures.
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of MACE endpoints
Time Frame: 3, 6 and 12 months
|
MACE = death, heart failure, myocardial infarction and stroke
|
3, 6 and 12 months
|
Change in aortic valve and mitral valve function
Time Frame: 3, 6 and 12 months
|
Echocardiography assessed aortic and mitral valve function
|
3, 6 and 12 months
|
Left anterior descending artery patency
Time Frame: 12 months
|
Patency of left anterior descending artery with cardiac CT
|
12 months
|
Presence of radiation pneumonitis
Time Frame: 12 months
|
Presence of radiation pneumonitis on CT
|
12 months
|
Development of complete heart block, atrial or ventricular arrhythmias
Time Frame: 3, 6 and 12 months
|
Cardiac device (ICD or pacemaker) check
|
3, 6 and 12 months
|
Change in LVOT gradient
Time Frame: 3, 6 and 12 months
|
Assessed with transthoracic echocardiography using same loading conditions as baseline
|
3, 6 and 12 months
|
Change in functional class
Time Frame: 6 and 12 months
|
Change in NYHA and CCS class from baseline
|
6 and 12 months
|
Change in frequency of syncope and pre-syncope
Time Frame: 6 and 12 months
|
Baseline to 6 and 12 months
|
6 and 12 months
|
Change in exercise capacity
Time Frame: 6 and 12 months compared to Baseline
|
6 minute Walk Test
|
6 and 12 months compared to Baseline
|
Change in health status
Time Frame: 6 and 12 months compared to Baseline
|
EQ-5D-5L
|
6 and 12 months compared to Baseline
|
Troponin T elevation
Time Frame: 1,2,3 days post ablation
|
Measurement of Trop T
|
1,2,3 days post ablation
|
Change in LV wall thickness
Time Frame: 6 months
|
CMR assessed thickness
|
6 months
|
Left ventricular ejection fraction (LVEF)
Time Frame: 3, 6 and 12 months
|
Measured on echocardiography
|
3, 6 and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Costas O'Mahony, FRCP, MD, Barts & The London NHS Trust
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIRA-HOCM 1.1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertrophic Cardiomyopathy
-
French Cardiology SocietyCompleted1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | 2- Obstructive Hypertrophic Cardiomyopathy | 3- Non Obstructive Hypertrophic CardiomyopathyFrance
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR)Enrolling by invitationCardiomyopathies | Hypertrophic Cardiomyopathy | Hypertrophic Obstructive Cardiomyopathy | Familial Hypertrophic CardiomyopathyCanada
-
University of Sao PauloCompletedNon-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyBrazil
-
Bristol-Myers SquibbActive, not recruitingHypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyDenmark, United States, Belgium, Czechia, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
-
Yonsei UniversityCompletedFamilial Hypertrophic CardiomyopathyKorea, Republic of
-
Hangzhou Valgen Medtech Co., LtdNot yet recruitingObstructive Hypertrophic CardiomyopathyChina
-
China National Center for Cardiovascular DiseasesNot yet recruitingObstructive Hypertrophic Cardiomyopathy
-
Bristol-Myers SquibbNot yet recruitingObstructive Hypertrophic CardiomyopathyKorea, Republic of
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.RecruitingObstructive Hypertrophic CardiomyopathyChina
-
Xiang WeiRecruitingNonobstructive Hypertrophic CardiomyopathyChina
Clinical Trials on Stereotactic body radiation therapy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Cancer Prevention Research Institute of TexasActive, not recruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Malignant Neoplasms of Urinary Tract | Oligometastatic Renal Cell CarcinomaUnited States
-
Roswell Park Cancer InstituteCompletedLung CancerUnited States
-
University of Texas Southwestern Medical CenterCompletedPain | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedLung CancerUnited States, Canada
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate AdenocarcinomaUnited States, Canada, Hong Kong, Switzerland, India, Ireland
-
Erasmus Medical CenterCompletedKlatskin TumorNetherlands
-
Paul W. Read, MDUnknownMetastatic Bone LesionUnited States
-
University of FloridaCompletedSpinal TumorsUnited States
-
M.D. Anderson Cancer CenterNot yet recruitingAdvanced Prostate CancerUnited States
-
Peking University Third HospitalRecruitingThoracic Cancer | Radiotherapy | Safety and EfficacyChina